Sonocine

What Sonocine does

SonoCiné, Inc. is a Reno, Nevada-based privately held medical technology company that develops and markets the SonoCiné Automated Whole Breast Ultrasound System (AWBUS), an FDA 510(k)-cleared imaging platform intended as an adjunct to mammography for breast cancer screening. The core technology is a robotics-assisted scanning attachment that connects to existing commercial ultrasound machines and captures approximately 3,000 high-resolution images (every 800 microns) of both breasts, including the axilla, presented in a video format for radiologist review. The system addresses a defined clinical problem: more than 45% of women have mammographically dense breast tissue, and an additional population has breast implants — both conditions can obscure cancers on mammograms. SonoCiné's published multi-center clinical trial of 6,425 exams found 46 cancers, of which 23 were visualized only by AWBUS and not detected by mammography.

The company monetizes through a combination of hardware sale or lease of the AWBUS unit to healthcare facilities (radiology practices, gynecologist offices, breast imaging centers, breast surgeons, and family physician practices), recurring per-examination fees billed by providers using CPT codes 76641 and 76642, and out-of-pocket patient payments ranging from $160 to $400 per exam where insurance does not cover the procedure. SonoCiné trains on-site ultrasound technologists, mammography technologists, and nurses, and operates a 'Find a Location' tool that directs patients to provider sites offering the exam. Distribution is direct-to-facility complemented by a patient-facing provider network, with all operations currently based in the United States.

SonoCiné was founded around the early-to-mid 2000s with technology development led by founder and chairman Dr. Kevin M. Kelly, who has worked on dense-breast cancer detection for approximately two decades; co-founder and president Carol Royce-Wilder and principal Thomas Stavros round out the disclosed leadership. The company has raised approximately $7.1 million in disclosed funding and remains small at 11–50 employees with a single-country footprint. Its proprietary assets include a patented hydrogel nipple pad and proprietary camisole, DICOM/PACS/RIS interoperability, and clinical evidence derived from the 2010 European Radiology multi-center trial.

Name

Sonocine

Legal name

SonoCiné, Inc.

Website

https://sonocine.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

SonoCiné develops and markets the FDA 510(k)-cleared AWBUS, a robotics-assisted automated whole-breast ultrasound system used as an adjunct to mammography. It serves women with dense breast tissue or implants, and is sold or leased to radiology, gynecology, and breast-imaging practices across the United States.

Ownership category

akta.pro rank

Product category

Breast Ultrasound Imaging Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Mammography & Breast Imaging Systems (HLAHABAF)

akta.pro secondary industry

Ultrasound & Echography Systems (HLAHABAD)

Keywords

• Automated breast ultrasound
• Breast cancer screening
• Adjunct mammography imaging
• Medical imaging device
• Dense breast imaging

Headquarters

HQ city

Reno

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Medical Equipment Sales/Leasing: SonoCiné AWBUS system is sold or leased to healthcare facilities including radiology practices, gynecologist offices, and breast imaging centers. The company offers financing and leasing programs tailored to client budgets.
2. Examination Reimbursement: Healthcare providers bill for SonoCiné AWBUS examinations using CPT codes 76641 (complete) and 76642 (limited). Reimbursement varies by insurance carrier. The exam is charged per breast.
3. Patient Examination Fees: Patients pay out-of-pocket for scans when insurance doesn't cover the procedure. Cost range is $160-400 per examination.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

SonoCiné develops and sells the AWBUS (Automated Whole Breast Ultrasound System), a robotics-assisted ultrasound scanning attachment that connects to existing commercial ultrasound machines. The system produces consistent, repeatable scans of the entirety of both breasts including the axilla, capturing approximately 3,000 images displayed in video format for radiologist review. It is FDA 510(k) cleared as an adjunct to mammography and is designed for women with dense breast tissue and/or breast implants.

Product overview

SonoCiné offers a unified medical imaging product portfolio centered on the SonoCiné AWBUS (Automated Whole Breast Ultrasound) system, an FDA 510(k) cleared automated whole breast ultrasound technology designed as an adjunct to mammography. The core system is complemented by proprietary patient comfort accessories including a camisole and patented hydrogel nipple pad. The AWBUS system connects to existing commercial ultrasound machines and generates DICOM files compatible with PACS and RIS systems. The technology is specifically designed to improve cancer detection in women with dense breast tissue and/or implants by providing consistent, repeatable scans of the whole breast.

Differentiator

Problem solved

Functional benefit

Products and services

• SonoCiné AWBUS (Automated Whole Breast Ultrasound System) An FDA 510(k) cleared automated whole breast ultrasound system that attaches to existing commercial ultrasound machines to deliver consistent, repeatable scans of both breasts including the axilla. The system robotically captures approximately 3,000 images displayed in a movie format for radiologist review, intended for use as an adjunct to mammography for women with dense breast tissue and/or implants.
• SonoCiné Proprietary Camisole A proprietary camisole that fits like a sports bra and holds the breasts in place during the AWBUS examination, providing patient modesty and supporting consistent imaging.
• Patented Hydrogel Nipple Pad A patented hydrogel nipple pad that enhances patient comfort and improves imaging of the nipple region during the SonoCiné AWBUS examination.

Quantifiable outcome

• Increases early-stage invasive breast cancer detection by up to 100% for women with dense breasts and/or implants
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature6 records

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• GE Healthcare: GE HealthCare offers the Invenia Automated Breast Ultrasound System (ABUS), the most established direct competitor to SonoCiné AWBUS. Both target automated whole-breast ultrasound as an adjunct to mammography for women with dense breast tissue.
• Hologic: Hologic is a leader in women's health imaging, including mammography, and through its acquisition of QT Ultrasound and associated ABUS programs competes directly in the automated breast ultrasound category alongside SonoCiné.
• Siemens Healthineers: Siemens Healthineers developed the ACUSON S2000 Automated Breast Volume Scanner (ABVS), a directly competing automated whole-breast ultrasound platform targeting the same adjunct-to-mammography use case as SonoCiné AWBUS.
• Delphinus Medical Technologies: Delphinus markets SoftVue, an automated whole-breast ultrasound tomography system intended as an adjunct to mammography. It addresses the same dense-breast screening problem SonoCiné targets.

Emerging players

• iSono Health: iSono Health is developing a portable, automated 3D breast ultrasound system with AI-based analytics. It is a smaller, earlier-stage competitor in the same automated breast ultrasound adjunct category.
• Volpara Health: Volpara provides breast density analytics and software that helps providers identify patients who would benefit from supplemental imaging such as SonoCiné AWBUS. Adjacent ecosystem player addressing the same dense-breast patient population.
• iCAD: iCAD provides AI-powered breast cancer detection and density assessment solutions used in mammography and tomosynthesis workflows. It is a software-driven participant in the broader breast imaging ecosystem where SonoCiné operates.
• Densitas: Densitas offers AI-based breast density and image quality analytics that help providers triage patients to supplemental imaging modalities such as SonoCiné AWBUS. It is an adjacent ecosystem enabler for dense-breast screening.

Broad incumbents

• Philips: Philips is a broad incumbent in medical imaging, including ultrasound platforms used in breast imaging. Its general-purpose ultrasound systems are the type of equipment SonoCiné AWBUS attaches to and competes with as integrated solutions.
• Hitachi Healthcare: Hitachi manufactures high-end diagnostic ultrasound systems used in breast imaging, including in some centers offering automated breast protocols. It competes as a broad incumbent ultrasound platform vendor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Sonocine
• YouTubeyoutube.com/user/SonoCine1
• Facebookfacebook.com/sonocine
• LinkedInlinkedin.com/company/sonocine

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sonocine